Is CYTR or JNJ a better dividend investment in 2026?

CYTR currently yields 11620.00% with a 5% 5-year dividend growth rate. JNJ yields 2.14% with 5.8% growth. The better choice depends on your goal: CYTR offers higher current income.

What is the dividend yield difference between CYTR and JNJ?

CYTR has a forward dividend yield of 11620.00% ($10.46/share annually). JNJ yields 2.14% ($5.20/share annually). The yield gap is 11617.86 percentage points.

Home › Compare › CYTR vs JNJ

CYTR vs JNJ: Dividend Comparison 2026

CYTR yields 11620.00% · JNJ yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CYTR wins by $242484085295883808.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CYTR

● Live price

11620.00%

Share price

$0.09

Annual div

$10.46

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$242484085295883808.00M

Annual income

$238,447,405,964,682,430,000,000.00

Full CYTR calculator →

JNJ

Johnson & Johnson

● Live price

2.14%

Share price

$242.49

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.5K

Annual income

$4,749.88

Full JNJ calculator →

Portfolio growth — CYTR vs JNJ

📍 CYTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CYTR	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CYTR + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CYTR pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTR

Annual income on $10K today (after 15% tax)

$987,700.00/yr

After 10yr DRIP, annual income (after tax)

$202,680,295,069,980,070,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$182.28/yr

After 10yr DRIP, annual income (after tax)

$4,037.40/yr

At 15% tax rate, CYTR beats the other by $202,680,295,069,980,070,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTR + JNJ for your $10,000?

CYTR: 50%JNJ: 50%

100% JNJ50/50100% CYTR

Portfolio after 10yr

$121242042647941904.00M

Annual income

$119,223,702,982,341,220,000,000.00/yr

Blended yield

98.34%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CYTR

Analyst Ratings

Buy

Hold

Consensus: Buy

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-5.7% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTR buys

JNJ buys

No recent congressional trades found for CYTR or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCYTRJNJ

Forward yield	11620.00% ✓	2.14%
Annual dividend / share	$10.46 ✓	$5.20
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$242484085295883808.00M ✓	$30.5K
Annual income after 10y	$238,447,405,964,682,430,000,000.00 ✓	$4,749.88
Total dividends collected	$242216106432564192.00M ✓	$15.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy

Year-by-year: CYTR vs JNJ ($10,000, DRIP)

Year	CYTR Portfolio	CYTR Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$1,172,700	$1,162,000.00	$10,594	$274.49	+$1.16M → CYTR
2	$128,607,817	$127,353,028.04	$11,294	$360.69	+$128.60M → CYTR
3	$13,190,478,160	$13,052,867,796.09	$12,133	$476.91	+$13190.47M → CYTR
4	$1,265,280,964,319	$1,251,167,152,687.08	$13,156	$635.42	+$1265280.95M → CYTR
5	$113,519,013,580,267	$112,165,162,948,446.42	$14,432	$854.61	+$113519013.57M → CYTR
6	$9,526,401,425,885,696	$9,404,936,081,354,810.00	$16,056	$1,162.76	+$9526401425.87M → CYTR
7	$747,812,665,514,758,900	$737,619,415,989,061,100.00	$18,175	$1,604.53	+$747812665514.74M → CYTR
8	$54,914,516,334,558,180,000	$54,114,356,782,457,390,000.00	$21,009	$2,252.68	+$54914516334558.16M → CYTR
9	$3,772,597,505,795,689,000,000	$3,713,838,973,317,711,700,000.00	$24,911	$3,229.73	+$3772597505795689.00M → CYTR
10	$242,484,085,295,883,800,000,000	$238,447,405,964,682,430,000,000.00	$30,458	$4,749.88	+$242484085295883808.00M → CYTR

CYTR vs JNJ: Complete Analysis 2026

CYTR — Stock

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Full CYTR Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this CYTR vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTR vs SCHD CYTR vs JEPI CYTR vs O CYTR vs KO CYTR vs MAIN CYTR vs ABBV CYTR vs MRK CYTR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.